Net margin is calculated as Net Income divided by its Revenue. C21 Investments's Net Income for the
three
months ended in Mar. 2026 was $-1.39 Mil. C21 Investments's Revenue for the
three
months ended in Mar. 2026 was $7.45 Mil. Therefore, C21 Investments's net margin for the quarter that ended in Mar. 2026 was -18.63%.
The historical rank and industry rank for C21 Investments's Net Margin % or its related term are showing as below:
CXXIF'
s Net Margin % Range Over the Past 10 Years
Min: -912.74 Med: -12.43 Max: 30.18
Current: -9.94
CXXIF's Net Margin % is ranked worse than 75.92% of 955
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs CXXIF: -9.94
C21 Investments (OTCPK:CXXIF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
C21 Investments Net Margin % Related Terms
C21 Investments Net Margin % Historical Data
* Premium members only.
The historical data trend for C21 Investments's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, C21 Investments's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C21 Investments Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, C21 Investments's Net Margin % distribution charts can be found below:
* The bar in red indicates where C21 Investments's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C21 Investments (CXXIF) has a Net Margin % of -18.63% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on C21 Investments and its competitors. According to the industry distribution chart, C21 Investments ranks #725 out of 955 companies in the Drug Manufacturers industry, placing it in the top 75.9%.
Is C21 Investments' Net Margin % too high?
C21 Investments' current Net Margin % is -18.63%. Based on the distribution chart, C21 Investments ranks #725 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, C21 Investments has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #725 out of 955 companies for Net Margin %. This places C21 Investments in the lower half of its industry. The industry median Net Margin % is 5.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current Net Margin % is -18.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.28, compared to a current price of $0.24 — trading 13% below its estimated fair value. The current Net Margin % is -18.63%. C21 Investments' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For C21 Investments (CXXIF), the current Net Margin % is -18.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.24 is trading 13% below its estimated GF Value™ of $0.28.
GuruFocus considers C21 Investments to be Modestly Undervalued.
Key valuation signals for CXXIF:
Net Margin %: -18.63%
GF Value™: $0.28 vs. price of $0.24 (13% below fair value)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
31GF Score
Get the complete analysis for CXXIF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
